Peter Sullivan

The House Education and Workforce Committee is adding to the bipartisan scrutiny of hospitals tomorrow with a markup of legislation that aims to crack down on anti-competitive practices and allow for more flexible contracts.

The Senate Finance Committee is planning a Sept. 18 hearing on the Inflation Reduction Act's drug pricing measures and the need to extend enhanced Affordable Care Act subsidies, sources tell Peter.

The China biotech crackdown cleared a major milestone last night when it passed the House — but it no longer has quite the bipartisan gloss that it had at the committee level, Peter reports.

A new coalition is pushing for renewing the enhanced Affordable Care Act subsidies that expire next year.

The collapse of Steward Health has increased scrutiny of private equity's role in health care.

Many GOP lawmakers are openly discussing killing a process that they've widely said artificially sets prices.

The Trump campaign's populist rhetoric on drug pricing is colliding with more traditional GOP concerns in Congress about heavy-handed government squelching pharmaceutical innovation.

Senators are set to relaunch the debate over revamping the drug patent system tomorrow, when the Judiciary Committee marks up a pair of bills that could raise the bar for who can challenge patents and what inventions are eligible for protection, Victoria reports.

The Steward saga also has become a vessel for many lawmakers' concerns about private equity investments in health care.

The Senate HELP Committee today unanimously voted to hold Steward Health Care CEO Ralph de la Torre in contempt over his refusal to comply with a subpoena to testify at a hearing on the health system's financial collapse and resulting harm to patients.